

Newsletter from Emotra AB (publ)

Göteborg, November 16, 2015

Presentations by Thorell and Sarchiapone at a conference in Łódź.

Lars-Håkan Thorell, the inventor of EDOR, and Emotra's scientific advisor Marco Sarchiapone will be holding a number of presentations at the Polish psychiatric association's annual conference, which will be held in Łódź on November 20–21, 2015. This conference is being held under the auspices of the world-leading suicide researcher Danuta Wasserman. Thorell and Sarchiapone will each be holding one presentation and leading a workshop at this conference.

During Poland's annual, national psychiatric conference, which is being held on November 20–21, 2015, Emotra's Lars-Håkan Thorell and the Company's prominent advisor, Marco Sarchiapone, will have an excellent opportunity to discuss EDOR and how this method can contribute to more efficient and effective suicide-prevention work in the future.

At the first session of this conference on the 20th, under the header "*Biological and psychosocial markers in suicides*", Marco Sarchiapone will hold the first of these presentations, titled "*Suicide and genetics*". Immediately after him and within the same session, Lars-Håkan Thorell will hold his presentation "*EDOR Test in suicide risk assessment*".

On the second day of this conference, Lars-Håkan Thorell will be holding his own workshop (which has an upper time limit of three hours) under the heading "*Electrodermal Reactivity Test in practice as support in suicide risk assessment*". Marco Sarchiapone will also be holding a workshop which at the same time functions as a course in "*Risk assessment of suicidal patients*".

The fact that risk assessment in general, and Emotra's method EDOR in particular, is receiving so much attention at this national psychiatric conference in Poland is a strong indication of the high hopes people have that EDOR will be able to help them make safer and more effective suicide risk assessments among depressed patients. Nonetheless, we must emphasise how important it is that the results of our ongoing clinical multi-centre study truly confirm the observations from earlier studies, in order for the method to be the longed-for solution to the psychiatric profession's problem of identifying those patients who are at risk of attempting suicide.

For further information, please contact: Claes Holmberg, CEO. Tel: +46 708 25 45 47, E-mail: claes@emotra.se

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company's method, EDOR, is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient's response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.